Glenn A. Eisenberg

October 9, 2026

JP Morgan Lowers Middleby Target to $145 While Maintaining Overweight. JP Morgan keeps an overweight rating on Middleby but cut its price target to $145 from higher levels. The new target sits below the current 52‑week high of $148.55 and near the analyst average of $155.67. With an RSI of 36.4, the stock is not yet oversold and is near a support level of $110.83. The downgrade may influence short‑term sentiment while the company remains valued at a 17.3 P/E.

September 25, 2026

Lumexa Imaging (LMRI) Valuation Analysis Published. A recent analysis suggests Lumexa Imaging Holdings may be trading at a discount to its estimated fair value, citing the company's imaging growth story. The stock is currently trading below the average analyst target price of $17.57. This valuation perspective provides context for investors assessing the company's current market position relative to its long-term potential.

October 4, 2026

Solventum Featured in Yahoo’s Overrated and Profitable Stock Lists. Yahoo highlighted Solventum in two recent articles. In one piece it was listed among stocks that may be overvalued, while the other article named it a profitable long‑term option. The coverage may influence how investors view the company’s valuation and growth prospects. The stock remains near the middle of its 52‑week range.

October 9, 2026

MiniMed Set for Medtronic Split-Off, Analysts Set New Targets. Medtronic has finalized the exchange ratio for the MiniMed split-off, a key corporate event for the stock. Meanwhile, Mizuho raised its price target to $28, while Barclays initiated coverage with a lower target of $22. Recent studies also highlighted that responding to MiniMed's diabetes alerts is linked to better glucose outcomes.

October 17, 2026

Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.

October 13, 2026

Barclays Upgrades Fortrea, Boosts Target to $23. Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.